LBPH

NASDAQ

Longboard Pharmaceuticals Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2021

News25/Ratings7

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. The company was founded in 2020 and is based in San Diego, California.

News · 26 weeks1-100%

2025-10-262026-04-19

Mix190d

Leadership1(100%)

Latest news

25 items

36dPR
Sensorion Reports Full-Year 2025 Results, Provides Corporate Update and Announces Release of Annual Report
GJB2-GT (SENS-601) CTA/IND-enabling studies progress, supported by regulatory interactions with FDA and EMA since Q3 2025, and on track for CTA submission in H1 2026 SENS-501 Audiogene trial ongoing; six-month efficacy data expected in Q1 2026 Strengthened balance sheet and shareholder registry via €60m financing in January 2026, including a €20m strategic investment from Sanofi; cash runway extended to end of H1 2027 Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reported its full-year 2025 results, provided a corp
386dPR
Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion's independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company's interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion's Board. This appointment by the Board of directors is performed b
497dSEC
SEC Form 15-12G filed by Longboard Pharmaceuticals Inc.
15-12G - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
499dSEC
SEC Form POSASR filed by Longboard Pharmaceuticals Inc.
POSASR - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
499dSEC
SEC Form RW WD filed by Longboard Pharmaceuticals Inc.
RW WD - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
499dSEC
SEC Form EFFECT filed by Longboard Pharmaceuticals Inc.
EFFECT - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
499dSEC
SEC Form EFFECT filed by Longboard Pharmaceuticals Inc.
EFFECT - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
499dSEC
SEC Form EFFECT filed by Longboard Pharmaceuticals Inc.
EFFECT - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
507dINSIDER
SEC Form 4 filed by Director Lynch Casey
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
507dINSIDER
SEC Form 4 filed by Director Le Goff Corinne
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
507dINSIDER
SEC Form 4 filed by Director Sekhri Paul J
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
507dINSIDER
SEC Form 4 filed by Director Schneider Phillip M
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
507dINSIDER
SEC Form 4 filed by Director Aurentz Vincent
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
507dINSIDER
Executive Vice President & CMO Kaye Randall closing all direct ownership in the company (SEC Form 4)
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
507dINSIDER
SEC Form 4 filed by Executive VP and CFO Roberts Brandi
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
507dINSIDER
President and CEO Lind Kevin Robert closing all direct ownership in the company (SEC Form 4)
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
507dSEC
SEC Form RW filed by Longboard Pharmaceuticals Inc.
RW - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
507dSEC
SEC Form S-8 POS filed by Longboard Pharmaceuticals Inc.
S-8 POS - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
507dSEC
SEC Form S-8 POS filed by Longboard Pharmaceuticals Inc.
S-8 POS - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
507dSEC
SEC Form S-8 POS filed by Longboard Pharmaceuticals Inc.
S-8 POS - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
507dSEC
SEC Form S-8 POS filed by Longboard Pharmaceuticals Inc.
S-8 POS - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
507dSEC
SEC Form POS AM filed by Longboard Pharmaceuticals Inc.
POS AM - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
507dSEC
SEC Form POS AM filed by Longboard Pharmaceuticals Inc.
POS AM - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
507dSEC
SEC Form POS AM filed by Longboard Pharmaceuticals Inc.
POS AM - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
507dSEC
Longboard Pharmaceuticals Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits
8-K - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)